Scholars@Duke
Jonathan Messerschmidt

Selected Publications

Rejection of benign melanocytic nevi by nevus-resident CD4+ T cells.

Journal Article Science advances · June 2021 Melanoma and melanocytic nevi harbor shared lineage-specific antigens and oncogenic mutations. Yet, the relationship between the immune system and melanocytic nevi is unclear. Using a patient-derived xenograft (PDX) model, we found that 81.8% of the transp ... Full text Cite

Divergent Roles of Epithelium-Derived Alarmins in Notch Signaling-Deficient Skin.

Journal Article The Journal of investigative dermatology · October 2020 Full text Cite

Immunity to commensal papillomaviruses protects against skin cancer.

Journal Article Nature · November 2019 Immunosuppression increases the risk of cancers that are associated with viral infection1. In particular, the risk of squamous cell carcinoma of the skin-which has been associated with beta human papillomavirus (β-HPV) infection-is increased by ... Full text Cite

Sea anemone model has a single Toll-like receptor that can function in pathogen detection, NF-κB signal transduction, and development

Journal Article Proceedings of the National Academy of Sciences · November 21, 2017 SignificanceToll-like receptors (TLR) are involved in pathogen recognition and defense in organisms from fruit flies to humans. Recent genomic evidence suggests that TLRs and their downstream signaling components ... Full text Open Access Cite

Cancer Clonal Theory, Immune Escape, and Their Evolving Roles in Cancer Multi-Agent Therapeutics.

Journal Article Current oncology reports · August 2017 Purpose of reviewThe knowledge base of malignant cell growth and resulting targets is rapidly increasing every day. Clonal theory is essential to understand the changes required for a cell to become malignant. These changes are then clues to thera ... Full text Open Access Cite

How Cancers Escape Immune Destruction and Mechanisms of Action for the New Significantly Active Immune Therapies: Helping Nonimmunologists Decipher Recent Advances.

Journal Article The oncologist · February 2016 UnlabelledWith the Food and Drug Administration and other worldwide regulatory authorities' approval of ipilimumab (Yervoy), sipuleucel-T (Provenge), nivolumab (Opdivo), and pembrolizumab (Keytruda), oncologic therapy has now moved into noncancer ... Full text Open Access Cite